Website Search
Find information on spaces, staff, and services.
Catalog Search
Videos, Slides, Films
Biomarkers in oncology : overview
- Author / Creator
- Available as
- Online
Details
- Creator
- Joe Duffy
- Format
- Videos, Slides, Films
- Language
- English
- Publication
-
- London, England : Henry Stewart Talks Ltd, 2016
- Physical Details
-
- 1 streaming video file (27 min.) : sound, color
- video file
- Retrieved April 9, 2024, from https://hstalks.com/bs/1118/.
- Introduction -- Tumor (bio)marker: definition -- Potential uses of tumor markers -- Cancer predisposing genes -- Genetic testing for cancer susceptibility: ASCO -- Use of tumor markers in screening -- Recommended cancer screening tests -- Markers under evaluation or previously evaluated -- PSA as a screening test for PCa -- PSA screening is controversial -- PSA as a screening test for PCa: way forward -- Ongoing trials evaluating PSA screening for Pca -- PSA screening: ACS guidelines -- PSA screening: USPSTF guidelines -- PSA screening: EGTM recommendations -- Use of tumor markers in aiding diagnosis -- When can merkers aid cancer diagnosis -- Use of markers in aiding the diagnosis of CUP -- Use of markers for differential diagnosis -- Diagnosis using CA 125: EGTM guidelines -- AFP as a diagnostic aid in HCC -- Use of tumor markers in assessing prognosis -- Markers can be used to determine prognosis -- Prognostic markers: clinical use -- Tissue markers and prognosis in breast cancer -- ER as a prognostic marker in breast cancer -- HER-2 as a prognostic marker in breast cancer -- uPA/PAI-1 prognostic marker in breast cancer -- uPA and PAI-1: ASCO recommendation (1) -- Oncotype DX test -- Oncotype DX test: ASCO recommendation -- MammaPrint -- Serum markers for determining prognosis -- Use of markers in predicting response to therpay -- Why do we need therapy predictive markers -- Response rates in patients with advanced cancers -- Predictive markers -- ER as a therapy predictive marker in breast cancer -- HER-2 as a predictive marker in breast cancer -- Herceptin in treatment of breast cancer -- HER-2 for predicting response to herceptin -- Emerging therapy predictive markers -- Use of markers in predicting therapy toxicity -- Markers for predicting anti-cancer agents toxicity -- Use of tumor markers in postoperative surveillance -- Markers in postoperative surveillance: rationale -- Tumor markers used in postoperative surveillance -- Critical question -- Intensive vs. control follow-up in CRC -- Follow-up of CRC patients: role of CEA -- Use of CEA in follow-up: EGTM recommendations -- Use of CEA in follow-up: ASCO recommendations -- Use of tumor markers in monitoring therapy -- Markers used in monitoring advanced disease -- Markers in surveillance and monitoring: caveats -- Acknowlegement